环孢素联合达那唑治疗难治性特发性血小板减少性紫癜的疗效观察

摘要

Objective To investigate the clinical effect of cyclosporine A(CSA)combined with danazol in the treatment of refractory idi-opathic thrombocytopenic purpura(ITP). Methods 45 patients with refractory ITP were randomly divided into two groups,the control group(n= 21 cases)was treated with vincristine and cyclophosphamide,and the observation group(n = 24 cases)was treated with CSA combined with danazol. Two groups were treated for 3 months. The clinical effect and the rate of adverse reaction of two groups were compared. Results The to-tal efficiency of the observation group(79. 2% )was significantly higher than that of the control group(66. 7% )( P < 0. 05);and there was no significant difference between the rate of adverse reaction in two groups during the treatment(45. 8% ,47. 6% )( P < 0. 05). Conclusion The treatment of CSA combined with danazol for refractory ITP had a significantly effect,safe and reliable. It was worthy of clinical application.%目的：探讨环孢素 A（CSA）联合达那唑治疗难治性特发性血小板减少性紫癜（ITP）的临床效果。方法45例难治性 ITP 患者随机分为两组，对照组（n =21例）给予长春新碱或环磷酰胺治疗，观察组（n =24例）给予 CSA 联合达那唑治疗，两组疗程均为3个月。治疗后比较两组疗效及不良反应发生率。结果观察组治疗总有效率（79.2％）明显高于对照组（66.7％），差异有统计学意义（ P <0.05）；两组治疗期间不良反应发生率比较（45.8％ vs.47.6％）无显著差异性（ P ﹥0.05）。结论 CSA 联合达那唑治疗难治性 ITP 疗效显著，安全可靠，值得临床推广应用。